Reported 3 days ago
This article explores Blueprint Medicines Corporation (BPMC) as one of the best mid cap biotech stocks to consider, particularly highlighting its promising pipeline and solid growth potential. With a market cap of $5.95 billion and a favorable analyst outlook, BPMC stands out despite challenges within a competitive sector. Analysts project significant gains for the stock, encouraging investment in its portfolio of life-changing drugs, though there's continuing debate about the overall viability of biotech investments.
Source: YAHOO